相似文献
1
Multimodality therapy for malignant pleural mesothelioma.
Ann Cardiothorac Surg. 2012 Nov;1(4):502-7. doi: 10.3978/j.issn.2225-319X.2012.11.12.
2
Aggressive multimodality therapy for malignant pleural mesothelioma.
Ann Thorac Surg. 1994 Jul;58(1):24-9. doi: 10.1016/0003-4975(94)91066-9.
3
Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
J Thorac Oncol. 2010 Mar;5(3):385-8. doi: 10.1097/JTO.0b013e3181cbf465.
4
The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
Anticancer Res. 2019 Nov;39(11):6241-6247. doi: 10.21873/anticanres.13833.
5
F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
Br J Radiol. 2018 Jun;91(1086):20170814. doi: 10.1259/bjr.20170814. Epub 2018 Mar 29.
6
Multimodality management of malignant pleural mesothelioma.
Chest. 1998 Jan;113(1 Suppl):61S-65S. doi: 10.1378/chest.113.1_supplement.61s.
7
Surgery for malignant pleural mesothelioma: why, when and what?
Lung Cancer. 2014 May;84(2):103-9. doi: 10.1016/j.lungcan.2014.01.021. Epub 2014 Feb 3.
8
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
J Thorac Cardiovasc Surg. 1999 Apr;117(4):759-65. doi: 10.1016/S0022-5223(99)70297-7.
9
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.
Eur Radiol. 2019 Jul;29(7):3696-3704. doi: 10.1007/s00330-018-5937-6. Epub 2019 Jan 28.
10
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
J Thorac Cardiovasc Surg. 2005 May;129(5):1010-7. doi: 10.1016/j.jtcvs.2004.10.040.
引用本文的文献
1
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
2
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.
J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.140. Epub 2023 May 30.
3
The Role of Surgery in Pleural Mesothelioma.
Cancers (Basel). 2024 Apr 28;16(9):1719. doi: 10.3390/cancers16091719.
4
Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma.
Transl Lung Cancer Res. 2023 Feb 28;12(2):190-192. doi: 10.21037/tlcr-22-906. Epub 2023 Feb 14.
5
Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.
Genome Med. 2022 Nov 15;14(1):127. doi: 10.1186/s13073-022-01129-4.
6
Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
J Thorac Oncol. 2022 Dec;17(12):1428-1432. doi: 10.1016/j.jtho.2022.08.017. Epub 2022 Sep 6.
7
The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma.
Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Jan 13;29(1):92-100. doi: 10.5606/tgkdc.dergisi.2021.20432. eCollection 2021 Jan.
8
Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
Front Oncol. 2019 Sep 26;9:961. doi: 10.3389/fonc.2019.00961. eCollection 2019.
9
Multimodality treatment of malignant pleural mesothelioma.
F1000Res. 2018 Oct 22;7. doi: 10.12688/f1000research.15796.1. eCollection 2018.
10
Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.
Sci Rep. 2018 Jul 6;8(1):10263. doi: 10.1038/s41598-018-28589-2.
本文引用的文献
1
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
Ann Thorac Surg. 2012 May;93(5):1658-65; discussion 1665-7. doi: 10.1016/j.athoracsur.2012.02.009.
2
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
AJR Am J Roentgenol. 2012 Feb;198(2):359-63. doi: 10.2214/AJR.11.7015.
3
The MARS feasibility trial: conclusions not supported by data.
Lancet Oncol. 2011 Nov;12(12):1093-4; author reply 1094-5. doi: 10.1016/S1470-2045(11)70307-2.
4
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
Lancet Oncol. 2011 Aug;12(8):763-72. doi: 10.1016/S1470-2045(11)70149-8. Epub 2011 Jun 30.
5
Update on malignant pleural mesothelioma.
Semin Respir Crit Care Med. 2011 Feb;32(1):102-10. doi: 10.1055/s-0031-1272874. Epub 2011 Apr 15.
6
Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?
Expert Rev Respir Med. 2011 Feb;5(1):49-63. doi: 10.1586/ers.11.1.
7
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study.
J Thorac Cardiovasc Surg. 2011 Jan;141(1):65-71. doi: 10.1016/j.jtcvs.2010.09.032.
8
A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.
J Thorac Oncol. 2010 Oct;5(10):1692-703. doi: 10.1097/JTO.0b013e3181ed0489.
9
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
Eur Respir J. 2010 Dec;36(6):1362-9. doi: 10.1183/09031936.00039510. Epub 2010 Jun 4.
10
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14.
Zotero 插件